Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. - Whitman-Walker

Masking Status:

Recommended (Optional)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.

You might also be interested in

Health System, Institute, News

April 7, 2025

U.S. HIV Researchers Reel at Widespread Cancellations to Domestic Funding

Institute, News

April 4, 2025

‘Cost us more in the long run’: Federal actions reverse progress on HIV epidemic, experts warn

Institute, News

March 31, 2025

On this Transgender Day of Visibility, We Cannot Allow This Administration to Erase Us